Nomura Asset Management CO LTD Sarepta Therapeutics, Inc. Transaction History

Nomura Asset Management CO LTD

Previous 0 NaN%

Previous $0 NaN%

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$124.33 - $156.75 $0 - $0	0 New	0 $0
Q2 2024 Aug 14, 2024	BUY	$113.33 - $163.85 $0 - $0	0 New	0 $0
Q1 2024 May 13, 2024	BUY	$93.7 - $141.53 $0 - $0	0 New	0 $0
Q4 2023 Feb 09, 2024	BUY	$67.31 - $124.76 $0 - $0	0 New	0 $0
Q3 2023 Nov 03, 2023	BUY	$102.5 - $123.59 $0 - $0	0 New	0 $0
Q2 2023 Aug 14, 2023	BUY	$106.4 - $157.19 $0 - $0	0 New	0 $0
Q1 2023 May 11, 2023	BUY	$117.53 - $155.99 $0 - $0	0 New	0 $0
Q4 2022 Feb 14, 2023	BUY	$100.86 - $132.13 $0 - $0	0 New	0 $0
Q3 2022 Nov 14, 2022	BUY	$75.71 - $119.24 $0 - $0	0 New	0 $0
Q3 2022 Nov 10, 2022	BUY	$75.71 - $119.24 $0 - $0	0 New	0 $0
Q3 2022 Nov 10, 2022	BUY	$75.71 - $119.24 $0 - $0	0 New	0 $0
Q3 2021 Nov 12, 2021	SELL	$65.97 - $92.48 $0 - $0	0 Closed	0 $0
Q2 2021 Aug 06, 2021	SELL	$69.38 - $86.75 $931,773 - $1.17 Million	-13,430 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$125.56 - $178.74 $163,228 - $232,362	1,300 Added 10.72%	13,430 $2.29 Million
Q2 2020 Aug 13, 2020	SELL	$93.0 - $171.7 $15,810 - $29,188	-170 Reduced 1.38%	12,130 $1.95 Million
Q3 2019 Nov 13, 2019	BUY	$72.81 - $156.91 $895,563 - $1.93 Million	12,300 New	12,300 $926,000
Q2 2019 Aug 13, 2019	BUY	$112.21 - $151.95 $0 - $0	0 New	0 $0
Q1 2019 May 10, 2019	BUY	$106.67 - $151.68 $0 - $0	0 New	0 $0
Q1 2019 May 10, 2019	BUY	$106.67 - $151.68 $0 - $0	0 New	0 $0
Q4 2018 Feb 12, 2019	BUY	$97.32 - $148.76 $0 - $0	0 New	0 $0
Q3 2018 Nov 07, 2018	BUY	$115.31 - $161.51 $0 - $0	0 New	0 $0
Q2 2018 Aug 03, 2018	BUY	$71.74 - $153.69 $0 - $0	0 New	0 $0
Q1 2018 May 14, 2018	BUY	$54.02 - $82.27 $0 - $0	0 New	0 $0

529

84.2M

2.06M

1.52M

Ticker SRPT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,567,904
Market Cap $10.7B
Description
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...

Get notified when there are updates to the investment portfolio of Nomura Asset Management CO LTD, based on Form 13F filings with the SEC.

Stay updated on Nomura Asset Management CO LTD with notifications on news.